Cyclerion Therapeutics Announces Merger Vote Results, 1-for-7 Reverse Split

What Happened
Cyclerion Therapeutics (CYCN) filed an 8‑K reporting results of its August 26, 2026 shareholder meeting held in connection with its planned merger with Korsana. There were 4,681,351 shares outstanding as of the July 17, 2026 record date and 3,896,779 shares were represented at the meeting (quorum). Shareholders approved several merger‑related proposals, including issuance of shares to Korsana stockholders, an increase in authorized common stock, and a reverse stock split (final ratio 1‑for‑7 approved by the Cyclerion Board after the meeting). The proposed redomestication to the Cayman Islands was not approved; Cyclerion will remain a Massachusetts corporation. The Cyclerion board nominees were elected and Ernst & Young LLP was ratified as independent auditors.

Key Details

• Meeting & quorum: Record date July 17, 2026; 3,896,779 shares represented at the Aug 26, 2026 meeting.
• Reverse stock split: Board approved a 1‑for‑7 reverse split (approved by shareholders). Estimated outstanding common shares to fall from ~4.7M to ~0.7M. No fractional post‑split shares will be issued; fractional entitlements will be cashed out at the Nasdaq closing price on the filing date of the amendment. Options and plan reserves will be proportionately adjusted.
• Authorized shares increased: Shareholder approval to raise authorized common stock from 400,000,000 to 700,000,000 shares. Vote: 3,874,047 for, 20,968 against, 1,764 abstain.
• Redomestication not approved: Proposal to redomesticate to the Cayman Islands failed (2,099,051 for; 1,296,575 against; 498,945 broker non‑votes). The Combined Company will remain a Massachusetts corporation; redomestication was not a condition to closing the Merger.
• Other approvals: Nasdaq stock‑issuance/change‑of‑control proposal approved (3,392,645 for); Korsana 2026 Stock Incentive Plan and Employee Stock Purchase Plan approved; advisory votes on merger‑related executive compensation and named‑executive officer pay approved; six director nominees elected (De Souza, Graul, Hecht, Higgins, Hyman, Katabi); Ernst & Young ratified as auditor.
• Expected listing: Following the Reverse Stock Split effective time and closing of the Merger, the Combined Company’s common stock is expected to trade on Nasdaq as “Korsana Biosciences, Inc.” (KRSA) on a split‑adjusted basis beginning September 9, 2026, with new CUSIP (23255M303) and ISIN (US23255M3034).

Why It Matters
These shareholder approvals clear key steps needed to complete the planned merger with Korsana and to prepare Cyclerion’s equity structure for the combined company. The 1‑for‑7 reverse split reduces the outstanding share count (and will proportionally change option exercise prices and plan reserves) and the authorized‑share increase creates capacity for post‑deal issuance. The failed Cayman redomestication means the combined business will remain incorporated in Massachusetts. Closing of the Merger (and the timing of the new ticker) remains subject to the conditions in the Merger Agreement and other customary closing matters.